Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Biomedicines|February 25, 2023
New Monoclonal Antibodies Specific for Different Epitopes of the Spike Protein of SARS-CoV-2 and Its Major Variants: Additional Tools for a More Specific COVID-19 DiagnosisSabrina Mariotti, Maria Vincenza Chiantore, Raffaela Teloni, et al.
Vaccine|October 2, 2018
Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1∗01Claudia Ferlito, Roberto Biselli, Sabrina Mariotti, et al.
Biomedicines|January 22, 2021
Immunogenicity of Viral Vaccines in the Italian MilitaryClaudia Ferlito, Roberto Biselli, Vincenzo Visco, et al.
Frontiers in Immunology|November 12, 2021
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High PotencySabrina Mariotti, Antonio Capocefalo, Maria Vincenza Chiantore, et al.
Biomedicines|January 21, 2022
Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after ImmunizationClaudia Ferlito, Vincenzo Visco, Roberto Biselli, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
The Oncologist|July 26, 2026
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study)Eleonora Gariazzo, Francesca Colamartini, Ornella Cantale, et al.
Pageof 7